Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (11425)	8/20/1999 1:40:00 PM
From: opalapril	Read Replies (2) \| Respond to of 17367

<<It is clear however that the result of the P II trauma trial was not as spectacular as the P II meningococcemia trial. But it had statistical significance on the endpoints being used in P III even if they selected after the P II trial was over.>> George or anyone: To what extent was there a dosage difference in te two P-2 trials? Is there any reason to think Neuprex dosages can or should be increased?

To: aknahow who wrote (11425)	8/20/1999 4:43:00 PM
From: Bluegreen	Respond to of 17367

You stated>>>>>>>>Yes, I have been watching. Seriously have you ever heard the expression, "What doesn't kill you makes you stronger" ???<<<<<<<<<<< Reminds me of learning how to swim......difficult part that made you stronger was getting out of the gunny sack first.

To: aknahow who wrote (11425)	8/20/1999 10:49:00 PM
From: Slugger	Respond to of 17367

Approval would still be great but even non approval will not mean that Neuprex does not work. Rather it will mean only that statistical significance was not demonstrated in this particular trial. I say only, because the reaction to less than spectacular results has already occurred. Exactly George I think that, even with a statistically insignificant failure, it will not be the end of XOMA. If the results look good--say 20 placebo deaths, 14 Neuprex-- but results are not statistically significant there will be an Amgen or Genentech that will be willing to buy them out and take a few more years to study Neuprex with the hopes that it hits big.